Page 3 - மருத்துவ சோதனை ப்ரோக்ர்யாம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from மருத்துவ சோதனை ப்ரோக்ர்யாம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In மருத்துவ சோதனை ப்ரோக்ர்யாம் Today - Breaking & Trending Today

Merck KGaA, Darmstadt, Germany, Reports Topline Data for Bintrafusp Alfa as Second-Line Monotherapy Treatment in Biliary Tract Cancer


Press release content from PR Newswire. The AP news staff was not involved in its creation.
Merck KGaA, Darmstadt, Germany, Reports Topline Data for Bintrafusp Alfa as Second-Line Monotherapy Treatment in Biliary Tract Cancer
March 16, 2021 GMT
Not intended for UK-based media
DARMSTADT, Germany, March 16, 2021 /PRNewswire/ Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced topline data from the Phase II INTR@PID BTC 047 study evaluating bintrafusp alfa as a monotherapy in the second-line treatment of patients with locally advanced or metastatic biliary tract cancer (BTC) who have failed or are intolerant of first-line platinum-based chemotherapy.
In the study of 159 patients, bintrafusp alfa demonstrated single-agent efficacy and durability with a manageable safety profile after more than nine months of follow-up, with an Independent Review Committee (IRC)-adjudicated objective response rate (ORR) of 10.1% (95% CI: 5.9% ....

United States , Prnewswire Merck Kga , Milind Javle , Md Anderson Cancer Center , Group Website , Clinical Trial Program , Merck Kga , Global Head Of Development For The Healthcare , Merck Kgaa , United Kingdom Based , Independent Review Committee , Cancer Center , Danny Bar Zohar , Global Head , Biliary Tract Cancer , Clinical Trial , Corporate News , Products And Services , Pr Newswire , Product Testing , Clinical Trials , Diseases And Conditions , Medical Research , Diagnosis And Treatment , ஒன்றுபட்டது மாநிலங்களில் , ம்ட் ஆண்டர்சன் புற்றுநோய் மையம் ,

Lilly's Mirikizumab Helps Patients Achieve Clinical Remission and Improves Symptoms in Adults with Ulcerative Colitis in 12-Week Phase 3 Induction Study

Merck Reports Topline Data for Bintrafusp Alfa as Second-Line Monotherapy Treatment in Biliary Tract Cancer

Tezepelumab Is The First Biologic To Significantly Reduce Exacerbations In Broad Population Of Patients With Severe, Uncontrolled Asthma


Tezepelumab Is The First Biologic To Significantly Reduce Exacerbations In Broad Population Of Patients With Severe, Uncontrolled Asthma
Data From Investigational Therapy Tezepelumab Phase 3 NAVIGATOR Trial in Patients With Severe Asthma Presented at the American Academy of Asthma Allergy & Immunology Annual Meeting
News provided by
Share this article
Share this article
THOUSAND OAKS, Calif., Feb. 26, 2021 /PRNewswire/  Amgen (NASDAQ:AMGN) and AstraZeneca today announced positive full results from the pivotal NAVIGATOR Phase 3 trial, which showed the potential of tezepelumab to be a first-in-class medicine in severe asthma. When added to standard of care (SoC), tezepelumab demonstrated a statistically significant and clinically meaningful reduction in the annualized asthma exacerbation rate (AAER) in patients with severe, uncontrolled asthma, compared to placebo. ....

United States , Puerto Rico , Trish Rowland , Megan Fox , Exchange Commission , Clinical Trial Program , Drug Administration Breakthrough Therapy Designation , Drug Administration , Beigene Ltd , American Academy , Asthma Allergy , Immunology Annual , North America , Amgen Board , Thousand Oaks , Uncontrolled Asthma , ஒன்றுபட்டது மாநிலங்களில் , ப்வெர்டோ ரிக்கோ , ட்ரிஷ் ரோலண்ட் , மேகன் நரி , பரிமாற்றம் தரகு , மருத்துவ சோதனை ப்ரோக்ர்யாம் , அமெரிக்கன் கலைக்கழகம் , ஆஸ்துமா ஒவ்வாமை , நோயெதிர்ப்பு ஆண்டு , வடக்கு அமெரிக்கா ,